Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $38.08

Janux Therapeutics, Inc. (NASDAQ:JANX) has received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $38.0833.

JANX has been the topic of a number of recent research reports. Wedbush lowered their target price on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. UBS Group cut shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $57.00 to $15.00 in a research note on Wednesday, April 15th. Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and dropped their price objective for the stock from $29.00 to $14.00 in a report on Monday, April 20th. Finally, Guggenheim reduced their target price on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a report on Friday, May 8th.

Insider Activity

In related news, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Nano Cap New Millennium Growth Fund L P purchased a new position in Janux Therapeutics during the 4th quarter valued at approximately $34,000. Versant Capital Management Inc boosted its position in shares of Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after acquiring an additional 784 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Janux Therapeutics in the fourth quarter valued at $51,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 3.7%

Shares of JANX stock opened at $15.00 on Friday. The stock has a market capitalization of $914.70 million, a P/E ratio of -8.15 and a beta of 2.52. The firm’s 50 day moving average is $14.86 and its 200 day moving average is $14.35. Janux Therapeutics has a 12-month low of $12.12 and a 12-month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. As a group, equities analysts predict that Janux Therapeutics will post -1.7 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.